Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

Lignende værker

• Reply: Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
  af: Michlmayr, A, et al.
  Udgivet: (2011)
• Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
  af: Michlmayr, A, et al.
  Udgivet: (2010)
• Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
  af: Mirzaei, Hamid Reza, et al.
  Udgivet: (2013)
• Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
  af: Won, Hye Sung, et al.
  Udgivet: (2020)
• Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
  af: Gamucci, T, et al.
  Udgivet: (2007)